MDCO's antiplatelet agent - cangrelor did not appear to be more effective than Plavix and did not appear equally or more effective in combination with standard meds than standard treatments alone. The Champion-Platform and Champion-PCI trials were stopped:
Market Data 
Markets 
AI
